For adults age 22+ with major depressive disorder on
antidepressant medication
Tap into your brain’s
power to take on
depression symptoms
Your brain can change. Rejoyn could help.
Rejoyn is a prescription app that helps reduce depression symptoms with brain training.
Need support with Rejoyn?
Call our nurse support line at 1-833-Y-REJOYN (1-833-973-5696) for assistance with your Rejoyn treatment. Available Monday through Friday,
Meet Rejoyn
Rejoyn, when used alongside your antidepressant medication, can help you treat depression symptoms differently. It is authorized by the FDA and provides 6 weeks of brain-training exercises and short skills-based therapy lessons.
Studied in a phase 3 clinical trial
In a clinical trial, adding Rejoyn to an antidepressant medication:
- Reduced depression
symptoms - With zero side effects
related to Rejoyn
The science behind Rejoyn
Rejoyn is designed to treat depression symptoms differently than medication. It taps into the brain's natural ability to change (known as neuroplasticity) with proven brain-training exercises and short skills-based therapy lessons.
The 6-week program is designed to:
-
Image
REBUILD neural connections -
Image
REWORK how your brain processes emotions -
Image
REDUCE depression symptoms
Interested in Rejoyn?
Start a virtual consult online or ask your prescriber
about Rejoyn.
Already have a prescription?
Find out what you need to know about starting your
Frequently asked questions
Yes. Unlike wellness apps, Rejoyn is classified as a medical device and was authorized by the FDA after being studied in a phase 3 clinical trial. It requires a prescription from a healthcare provider. Start a virtual consult to get a prescription.
Rejoyn was effective in a clinical trial of adults age 22+ with major depressive disorder, also known as depression, who were also taking an antidepressant medication. After they finished the 6-week program, the effect of Rejoyn was measured. Results showed that using Rejoyn reduced depression symptoms. On average, people reported that Rejoyn reduced their depression severity from moderately severe to mild,* and clinicians reported that Rejoyn reduced depression severity from moderately ill to mildly ill.† During the month following treatment with Rejoyn, there was a trend toward continued improvement. Learn more about results with Rejoyn.
*Measured by a participant-reported outcome scale of depression, Patient Health Questionnaire (PHQ-9). In the control arm, people using a Sham app reported reduced depression severity from moderately severe to moderate.
†Measured by a clinician-reported outcome scale of depression, Clinical Global Impressions-Severity Scale (CGI-S).
You can consent to sharing your app data with Rejoyn nurses for treatment support. Learn more about setting your app data preferences on our FAQ page.
Otsuka Precision Health (OPH) is committed to protecting the privacy and security of your information. OPH may use, store, and share your data as described in the OPH Privacy Policy and in a manner consistent with your privacy choices, including how you can correct, change, or delete certain personal information OPH collects about you in connection with your use of this live chat service.
The Rejoyn Privacy Notice and Terms of Use can be reviewed in the app within the "Important Information" section of your profile. The App Instructions for Use can show you where they're located. Please see our Privacy Notice and Terms of Use for more information.
